Clinical trials
Moderate to Severe Asthma clinical trials
Below are recruiting moderate to severe asthma clinical trials, each written for real people, not researchers. We’re tracking 53 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04160910RecruitingPhase 2
Studying 5HTP to manage asthma symptoms in kids
This Phase 2 study tests whether 5HTP can help regulate asthma in children and teens who have mild to moderate asthma linked to allergies. It may be an option if your symptoms are allergy-related and you can follow study visits and questionnaires.
Indianapolis, IndianaAges 8–18 - NCT07486401Recruiting
Blood eosinophil-guided asthma care in primary care
This trial tests whether using a blood test (eosinophil count) to guide asthma treatment works better than usual care for people with mild to moderate asthma. If you have asthma and are on step 1-3 treatment, this study could help improve your symptom control.
SingaporeAges 21–65 - NCT07348302RecruitingPhase 3
Allergy tablet for dust mite rhinitis and asthma
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
Nueve de Julio, Buenos AiresAges 12–65 - NCT07192016RecruitingPhase 4
MRI study of triple inhaler for COPD with breathlessness
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
London, OntarioAges 50–85 - NCT07723144Recruiting
Identifying sleep apnea biomarkers
This study compares blood samples from people with moderate-to-severe sleep apnea and those without sleep apnea to find markers that could help diagnose or treat the condition. Half of those with sleep apnea will start CPAP therapy right away, while others wait before starting.
Bialystok, Podlaskie VoivodeshipAges 18–65 - NCT07668518RecruitingPhase 1/Phase 2
Study of KIT2014 for moderate to severe COPD
This trial tests a new medicine called KIT2014 in people with moderate to severe COPD. It aims to see if the drug is safe, tolerable, and helps improve breathing and COPD symptoms.
Charlestown, New South WalesAges 40–80 - NCT07640451RecruitingPhase 2
HRS-9821 inhalation treatment for moderate to severe COPD
This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.
Shanghai, Shanghai MunicipalityAges 40–80 - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Birmingham, AlabamaAges 18–65 - NCT07464587RecruitingPhase 3
Inhaled study drug for moderate to severe copd
This trial tests an inhaled medication (given through a nebulizer) to see how well it improves breathing and quality of life in people with moderate-to-severe COPD. It may help reduce symptoms and flare-ups, but will require regular visits and lung function tests.
Chizhou, AnhuiAges 40–80 - NCT07418736RecruitingPhase 2
CM326 for moderate to severe COPD
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Beijing, Beijing MunicipalityAges 40–85 - NCT07402551RecruitingPhase 2
Testing RC1416 injection for COPD flare-ups
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
Hefei, AnhuiAges 40–85 - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT07311369RecruitingPhase 2
Testing a new pain tablet after abdominal surgery
This trial tests a new pain tablet (HL-1186) for people having abdominal surgery. It aims to see if the tablet is safe and works well to manage pain after the operation.
Changsha, HunanAges 18–75 - NCT06890260Recruiting
Electroacupuncture plus microneedle for allergic rhinitis
This trial tests a 4-week treatment of electroacupuncture combined with microneedle knife for people with moderate to severe allergic rhinitis. It may help reduce symptoms without relying on standard allergy medications.
Hangzhou, ZhejiangAges 18–75 - NCT07207954RecruitingPhase 1
Testing LFD-200 in healthy adults and adults with rheumatoid arthritis
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
MelbourneAges 18–75 - NCT07069829Recruiting
Living with COPD: A study on Breztri/Trixeo
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
Buenos AiresAges 30–80 - NCT07039669RecruitingPhase 3
Study of 611 for moderate to severe COPD in adults
This trial tests a new medicine called 611 for people with moderate to severe COPD. It aims to see if adding 611 to your current treatments can help prevent flare-ups and improve symptoms.
Beijing, Beijing MunicipalityAges 40–85 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT05896800Recruiting
Inhaled nitric oxide for moderate to severe COPD symptoms
This study tests whether inhaled nitric oxide gas can improve outcomes in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It may help reduce breathing problems by targeting how airways and blood vessels respond in the lungs.
Nanjing, JiangsuAges 40–75 - NCT04815668Recruiting
Acupuncture for moderate-to-severe seasonal allergy rhinitis
This trial tests whether acupuncture at a specific spot behind the nose can reduce symptoms from seasonal allergies (triggered by things like grass or birch pollen). It may help if your allergy symptoms are moderate to severe and have lasted for a long time.
BeijingAges 18–75 - NCT06436534Recruiting
Ganciclovir for stubborn allergic rhinitis
This study tests whether an antiviral medicine called ganciclovir (in capsule form) can help people with stubborn moderate-to-severe allergic rhinitis that doesn't improve with standard treatments. If you have year-round allergies to dust mites and your symptoms are still bothersome, this trial may be an option for you.
Wuhan, HubeiAges 18–65 - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT07780656RecruitingPhase 3
Felcorekibart for chronic obstructive pulmonary disease (COPD)
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
Miami, FloridaAges 40–80 - NCT07780669RecruitingPhase 3
Study of a new drug for moderate to severe COPD in smokers
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
Doral, FloridaAges 40–80
Hear when a new Moderate to Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe asthma?
- Yes. Clin2 currently lists 53 recruiting moderate to severe asthma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe asthma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe asthma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.